Results of the PROPINE randomized controlled trial: determining the ever-elusive target, the optimal plan for relapses of nephrotic syndrome in children
- PMID: 33509352
- DOI: 10.1016/j.kint.2020.10.034
Results of the PROPINE randomized controlled trial: determining the ever-elusive target, the optimal plan for relapses of nephrotic syndrome in children
Abstract
Best treatments for initial presentation and relapses in children with nephrotic syndrome (NS) are still to be defined. The PROPINE study, published in this issue of Kidney International, demonstrates for relapse of childhood NS, the non-inferiority of a short taper (over 36 days) after remission with steroids. This study reinforces the need for more well-designed studies and the incorporation of predictive biomarkers, genetic studies, and other details to personalize treatment for each child with idiopathic NS.
Keywords: glomerular disease; nephrotic syndrome; pediatric nephrology.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children.Kidney Int. 2021 Feb;99(2):475-483. doi: 10.1016/j.kint.2020.09.024. Epub 2020 Nov 2. Kidney Int. 2021. PMID: 33152448 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous